ETF / Index • GICS Health Care & Pharma • SIC 6726
$184.87 ▲ +4.32
(+2.35%)
MKT CAP: $40.00B • VOL: 18.67M
52W L $142 52W H $188
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$155
MEDIAN
$207
MEAN
$211
HIGH
$251
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE XLV TAPE
XLV // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $223.69 | $212.60 | 2025-02-14 | $168.23 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $232.94 | $218.15 | 2025-02-06 | $173.78 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $210.75 | $203.36 | 2025-01-29 | $177.48 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $188.57 | — | 2025-01-17 | $181.17 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $162.69 | $175.63 | 2025-01-09 | $164.53 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $220.00 | $192.26 | 2024-12-18 | $160.84 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $179.32 | $186.72 | 2024-12-04 | $171.93 | -4.3% | 48% | C |